[Diagnosis and follow-up value of quantitative examination of MMP9 in the urine of BTCC patients].
OBJECTIVE
To explore the value of quantitative examination of total matrix metalloproteinase-9 (MMP9) in the urine of bladder transitional cell carcinoma (BTCC) patients.


METHODS
The urine samples of 41 patients with BTCC were examined by the quantitative enzyme immune assay (EIA). Nine cases free from disease after operation, 9 cases with precancerous lesions, 13 cases with other urological diseases, and 8 healthy volunteers as the control group were examined.


RESULTS
The content of total MMP9 in the BTCC group was significantly higher than that in the other groups, and the content increased with the tumor grade and stage aggravation. The urine total MMP9 had no significant difference between the primary tumors and recurrence ones. The sensitivity of diagnosis was 90.2%, and the specificity was 78.7% when the cutoff was 1.5 ng/ml.


CONCLUSIONS
The content of total MMP9 in the urine of patients with BTCC is higher than that in healthy cases and other urological diseases cases. MMP9 may be a new valuable tumor marker for the screening, diagnosis and follow-up for patients with BTCC.
Zhang
Xue-pei
XP
Department of Urology, Xiangya Hospital, Central South University, Changsha 410008, China.
Shen
Peng-fei
PF
Zhou
Cheng
C
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D014408:Biomarkers, Tumor / Q000652:urine; D002295:Carcinoma, Transitional Cell / Q000652:urine*; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008297:Male; D020780:Matrix Metalloproteinase 9 / Q000652:urine*; D008875:Middle Aged; D011230:Precancerous Conditions / Q000652:urine; D012008:Recurrence; D001749:Urinary Bladder Neoplasms / Q000652:urine*
D014408:Biomarkers, Tumor; D020780:Matrix Metalloproteinase 9